Compare DuPont de Nemours Inc (DD) vs Pfizer Inc (PFE) Price & Performance

DuPont (DD) trades at $142.48, down 1.06% on the day, with a bullish technical signal from moving averages and strong analyst support. The company reported Q2 2026 earnings that beat expectations, with EPS of $1.88 versus $1.76 expected, and raised its full-year 2026 outlook, driven by healthcare, industrial water, and aerospace demand. However, 2025 fundamentals show a net loss of $779 million on revenue of $6.85 billion, with a high P/E ratio of 61.15 indicating premium valuation.

The outlook is cautiously optimistic, supported by earnings momentum and innovation awards, but risks include ongoing legal settlements over PFAS chemicals and thin net margins. The consensus price target of $232.80 suggests significant upside potential if operational improvements continue.

Pfizer (PFE) trades at $26.74, up 2.06% today, with a bullish technical signal from moving averages and a consensus analyst price target of $27.86. Recent quarters show consistent earnings beats, though revenue has moderated from pandemic peaks. The company maintains a strong cash position of $20.48 billion (2024) and a dividend yield supported by a $0.43 per share payout. Key developments include a focus on obesity and oncology pipelines, with several catalysts expected in 2026.

The outlook balances a stable dividend and pipeline potential against post-COVID revenue normalization and patent cliff risks. Near-term upside exists if pipeline catalysts materialize, but investors face headwinds from competitive pressures and projected net income margin compression to 6.8% in 2026. The stock's valuation at a P/E of 35.21 appears elevated relative to earnings growth, warranting caution despite technical strength.